Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria

NCT00421109 is registered in ClinicalTrials.gov with Faes Farma, S.A. as lead sponsor.

NCT NCT00421109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00421109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomised, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Levocetirizine 5 mg for the Treatment of Chronic Idiopathic Urticaria
Lead sponsor
Faes Farma, S.A.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2006
Completion date
July 31, 2007
Enrollment
522 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria